封面
市場調查報告書
商品編碼
1301075

乳腺癌藥物市場規模、份額及趨勢分析報告:按治療方法(靶向治療、激素治療)、按分銷渠道(醫院藥房、零售藥房)、按癌症類型(激素受體、HER2+)、細分市場預測,2023- 2030年

Breast Cancer Drugs Market Size, Share & Trends Analysis Report By Therapy (Targeted, Hormonal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Cancer Type (Hormone Receptor, HER2+), And Segment Forecasts, 2023 - 2030

出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

乳腺癌藥物市場增長和趨勢

根據Grand View Research, Inc.最新報告,2023年至2030年全球乳腺癌藥物市場規模將以9.09%的複合年增長率增長, 2030年預計到2020年將達到586.9億美元。

這種增長主要是由疾病患病率上升、研發投資增加以及知名公司的舉措推動的。 此外,個性化醫療的趨勢正在推動市場增長,即根據患者的基因構成為個體患者量身定制治療方案。 基因組學和分子生物學的進步促進了靶向療法的發展,這些療法比傳統化療更有效且副作用更少。 世界各國政府都在投資新藥和治療方法的研發。 例如,美國國家癌症研究所就設立了多個研究所。

例如,國家癌症研究所啟動了多項研究計劃來開發新藥並提高現有治療方法的有效性。 同樣,2023年1月,澳大利亞政府宣布將投資1601萬美元用於開發針對女性的治療方法。 該投資將通過國家健康和醫學研究委員會的資助計劃資助 23 個項目,包括乳腺癌研究。 非營利組織的參與增加預計將推動市場的增長。 例如,2022 年 6 月,乳腺癌組織 Susan G. Komen 宣布將獲得 2100 萬美元,用於支持 26 個學術機構的約 48 個研究項目。 大部分資金將用於侵襲性乳腺癌的研究,隨後進行臨床試驗和研究以縮小差距。

此外,乳腺癌患者也受到了這一流行病的影響,因為他們的免疫系統較弱,導致他們患 COVID-19 並發症的風險增加。 結果,許多患者不得不推遲或取消治療,影響了對該藥物的需求。 此外,疫情對經濟的影響也對市場產生了影響。 失業和收入水平下降影響了購買藥品的能力。 結果,產品需求下降,對市場產生中短期影響。 藥品價格對市場影響較大。 較高的價格可能會限制使用並影響需求,而較低的價格可能會增加可用性並增加需求。 因此,利益相關者必須平衡對負擔得起的藥物的需求與持續研究和開發以改善治療選擇的需求。

乳腺癌藥物市場報告亮點

  • 免疫治療類型將成為2022年市場增長最快的治療領域之一。 免疫療法通過刺激患者的免疫系統識別和攻擊癌細胞來發揮作用。 這種方法在包括乳腺癌在內的各種類型的癌症中都顯示出了有希望的結果。
  • 按類型劃分,激素受體細分市場在 2022 年佔據了大部分市場份額。 激素受體陽性乳腺癌是最常見的亞型。 因此,激素治療藥物是治療的主要手段。
  • 2022 年,醫院藥房分銷渠道佔據最大份額。 醫院藥房通常比零售藥房和其他渠道提供更廣泛的專科藥物和治療方法。
  • 不斷上升的乳腺癌患病率、高昂的醫療保健支出以及持續的研發工作將使北美在 2022 年佔據全球行業的主導地位。

內容

第一章調查方法及範圍

  • 市場細分
  • 市場定義和目的
  • 調查方法
  • 信息獲取
    • 購買的數據庫
    • Gvr 內部數據庫
    • 次要信息
    • 初步調查
  • 信息或數據分析
    • 數據分析模型
  • 市場形成和驗證
  • 型號詳細信息
    • 產品流分析
  • 輔助信息列表
  • 縮寫列表
  • 主要信息列表

第 2 章執行摘要

  • 市場概況
  • 治療和癌症類型快照
  • 分銷渠道快照
  • 競爭格局快照

第三章市場變量、趨勢和範圍

  • 市場細分和範圍
  • 市場體系展望
    • 母公司市場前景
    • 相關/補充市場前景
  • 市場趨勢和展望
  • 市場動態
    • 全球癌症發病率和患病率不斷上升
    • 大量投資於研發
    • 癌症生物學和藥理學的技術進步
  • 市場製約因素分析
    • 嚴格的監管準則
    • 專利藥品的有效期
    • 與化療相關的並發症
  • 2022 年採用率和增長前景圖
  • 商業環境分析
    • SWOT 分析:按因素(政治/法律、經濟/技術)
    • 波特五力分析
  • COVID-19 的影響分析

第 4 章治療業務分析

  • 乳腺癌藥物市場:治療變化分析
  • 靶向治療
    • 乳腺癌藥物市場,靶向治療,2018-2030 年(百萬美元)
    • Abemasiclib
    • Ado-曲妥珠單抗 emtansine
    • 依維莫司
    • 曲妥珠單抗
    • Ribociclib
    • 帕博西尼
    • 帕妥珠單抗
    • 奧拉帕尼
    • 其他
  • 激素療法
    • 乳腺癌藥物市場,激素治療,2018-2030 年(百萬美元)
    • 選擇性雌激素受體調節劑 (Serms)
    • 芳香□抑製劑
    • 雌激素受體下調劑 (Erds)
  • 化療
    • 乳腺癌藥物市場,化療,2018-2030 年(百萬美元)
  • 免疫治療
    • 乳腺癌藥物市場,免疫療法,2018-2030 年(百萬美元)

第五章癌症類型業務分析

  • 乳腺癌藥物市場:癌症類型的變異分析
  • 激素受體
    • 乳腺癌藥物市場,激素受體,2018-2030 年(百萬美元)
  • 她2+
    • 乳腺癌藥物市場,HER2+,2018-2030(百萬美元)

第六章分銷渠道業務分析

  • 乳腺癌藥物市場:分銷渠道波動分析
  • 醫院藥房
    • 乳腺癌藥物市場,醫院藥房,2018-2030 年(百萬美元)
  • 零售藥店
    • 乳腺癌藥物市場,零售藥房,2018-2030 年(百萬美元)
  • 其他
    • 乳腺癌藥物市場,其他,2018-2030 年(百萬美元)

第七章區域業務分析

  • 2022 年和 2030 年按地區劃分的乳腺癌藥物市場份額
  • 北美
    • SWOT分析
    • 2018-2030 年北美乳腺癌藥物市場(按治療方法)(百萬美元)
    • 2018-2030 年北美乳腺癌藥物市場(按癌症類型劃分)(百萬美元)
    • 2018-2030 年北美乳腺癌藥物市場(按分銷渠道)(百萬美元)
    • 美國
    • 加拿大
  • 歐洲
    • SWOT分析
    • 2018-2030 年歐洲乳腺癌藥物市場(按療法)(百萬美元)
    • 2018-2030 年歐洲乳腺癌藥物市場(按癌症類型)(百萬美元)
    • 2018-2030 年歐洲乳腺癌藥物市場(按分銷渠道)(百萬美元)
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • SWOT分析
    • 2018-2030 年亞太地區乳腺癌藥物市場(按治療方法)(百萬美元)
    • 2018-2030 年亞太地區乳腺癌藥物市場(按癌症類型)(百萬美元)
    • 2018-2030 年亞太地區乳腺癌藥物市場(按分銷渠道)(百萬美元)
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳大利亞
    • 泰國
  • 拉丁美洲
    • SWOT分析
    • 2018-2030 年拉丁美洲乳腺癌藥物市場(按治療方法)(百萬美元)
    • 2018-2030 年拉丁美洲乳腺癌藥物市場(按癌症類型劃分)(百萬美元)
    • 2018-2030 年拉丁美洲乳腺癌藥物市場(按分銷渠道)(百萬美元)
    • 巴西
    • 墨西哥
    • 阿根廷
  • MEA
    • SWOT分析
    • 2018-2030 年 MEA 乳腺癌藥物市場(按治療方法)(百萬美元)
    • 2018-2030 年 MEA 乳腺癌藥物市場(按癌症類型)(百萬美元)
    • 2018-2030 年 MEA 乳腺癌藥物市場(按分銷渠道)(百萬美元)
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 科威特

第 8 章競爭格局

  • 公司分類
  • 戰略規劃
    • 推出新產品
    • 合作夥伴關係
    • 獲取
    • 合作
    • 籌款
  • 2022 年公司市場份額分析
  • 公司簡介
    • Novartis Ag
    • Pfizer, Inc
    • Merck Kgaa
    • Janssen Pharmaceuticals, Inc.
    • Celgene Corporation, Inc.
    • Genzyme Corporation
    • F. Hoffmann-La Roche Ltd
    • Astrazeneca
    • Abbvie Inc.
    • Bristol-Myers Squibb Company
    • Macrogenics, Inc.
    • Celldex Therapeutics
    • Onyx Pharmaceuticals Inc.

第9章 結論

Product Code: GVR-3-68038-041-5

Breast Cancer Drugs Market Growth & Trends

The global breast cancer drugs market size is expected to reach USD 58.69 billion by 2030, registering a CAGR of 9.09% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth is majorly attributed to the rising disease prevalence, increasing R&D investments, and initiatives by prominent players. Moreover, the trend towards personalized medicine, which involves tailoring treatment for individual patients based on their genetic makeup, is driving the growth of the market. Advances in genomics and molecular biology have led to the development of targeted therapies, which are more effective and have fewer side effects than traditional chemotherapy. Governments around the world are investing in the research and development of new drugs and treatment options. For instance, the U.S.

National Cancer Institute has established several research programs to develop new drugs and improve the efficacy of existing treatments. Similarly, in January 2023, the Australian government announced an investment of USD 16.01 million in developing targeted treatments for women. The investment is expected to fund 23 projects including research on breast cancer through a grant program by the National Health and Medical Research Council. The increasing participation of non-profit organizations is anticipated to propel the market growth. For instance, in June 2022, Susan G. Komen, a breast cancer organization, announced to receive USD 21 million to support around 48 research projects at 26 academic institutions. The majority of funds are allocated to research on aggressive breast cancers, followed by clinical trials and research on eliminating the disparities in the market.

Furthermore, breast cancer patients have been affected by the pandemic as the risk of complications from COVID-19 increases due to their weakened immune systems. As a result, many patients had to postpone or cancel their treatments, which affected the demand for drugs. Moreover, the economic impact of the pandemic also affected the market. The loss of employment or deduction in the income level impacted the affordability of drugs. This, in turn, resulted in reduced product demand and short to medium-term effects on the market. The cost of drugs has a significant impact on the market. High drug prices can limit their usage and affect demand, while lower prices can increase accessibility and demand. Thus, stakeholders need to balance the need for affordable drugs with the need for continued R&D to improve treatment options.

Breast Cancer Drugs Market Report Highlights

  • The immunotherapy type segment was one of the fastest-growing areas of therapy in the market in 2022. Immunotherapy works by stimulating the patient's immune system to recognize and attack cancer cells. This approach has shown promising results in a variety of types, including breast cancer
  • By type, the hormone receptor segment captured the majority of the market share in 2022. Hormone receptor-positive breast cancer is the most common subtype. As a result, hormone therapy drugs have been a mainstay of treatment
  • The hospital pharmacies distribution channel segment held the largest share in 2022. Hospital pharmacies often have access to a wide range of specialized drugs and therapies as compared to retail pharmacies or other channels
  • In terms of revenue share, North America had a dominant position in the global industry in 2022 owing to the increased prevalence of breast cancer, high healthcare expenditures, and ongoing R&D activities

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1 Market Segmentation
  • 1.2 Market Definitions And Objectives
    • 1.2.1 Objective - 1
    • 1.2.2 Objective - 2
    • 1.2.3 Objective - 3
  • 1.3 Research Methodology
  • 1.4 Information Procurement
    • 1.4.1 Purchased Database
    • 1.4.2 Gvr's Internal Database
    • 1.4.3 Secondary Sources
    • 1.4.4 Primary Research
  • 1.5 Information Or Data Analysis
    • 1.5.1 Data Analysis Models
  • 1.6 Market Formulation & Validation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis
  • 1.8 List Of Secondary Sources
  • 1.9 List Of Abbreviations
  • 1.10 List Of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Therapy And Cancer Type Snapshot
  • 2.3. Distribution Channel Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends And Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Increased Incidence And Prevalence Rate Of Cancer Worldwide
    • 3.4.2. High Investment In R&D
    • 3.4.3. Technological Advancement In Cancer Biology & Pharmacology
  • 3.5. Market Restraint Analysis
    • 3.5.1. Stringent Regulatory Guidelines
    • 3.5.2. Expiry Of Patented Drugs
    • 3.5.3. Complications Associated With Chemotherapy
  • 3.6. Penetration And Growth Prospect Mapping 2022
  • 3.7. Business Environment Analysis
    • 3.7.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.7.2. Porter's Five Forces Analysis
  • 3.8. Covid-19 Impact Analysis

Chapter 4. Therapy Business Analysis

  • 4.1. Breast Cancer Drugs Market: Therapy Movement Analysis
  • 4.2. Targeted Therapy
    • 4.2.1. Breast Cancer Drugs Market, Targeted Therapy, 2018 - 2030 (USD Million)
    • 4.2.2. Abemaciclib
      • 4.2.2.1. Breast Cancer Drugs Market, Abemaciclib, 2018 - 2030 (USD Million)
    • 4.2.3. Ado-Trastuzumab Emtansine
      • 4.2.3.1. Breast Cancer Drugs Market, Ado-Trastuzumab Emtansine, 2018 - 2030 (USD Million)
    • 4.2.4. Everolimus
      • 4.2.4.1. Breast Cancer Drugs Market, Everolimus, 2018 - 2030 (USD Million)
    • 4.2.5. Trastuzumab
      • 4.2.5.1. Breast Cancer Drugs Market, Trastuzumab, 2018 - 2030 (USD Million)
    • 4.2.6. Ribociclib
      • 4.2.6.1. Breast Cancer Drugs Market, Ribociclib, 2018 - 2030 (USD Million)
    • 4.2.7. Palbociclib
      • 4.2.7.1. Breast Cancer Drugs Market, Palbociclib, 2018 - 2030 (USD Million)
    • 4.2.8. Pertuzumab
      • 4.2.8.1. Breast Cancer Drugs Market, Pertuzumab, 2018 - 2030 (USD Million)
    • 4.2.9. Olaparib
      • 4.2.9.1. Breast Cancer Drugs Market, Olaparib, 2018 - 2030 (USD Million)
    • 4.2.10. Others
      • 4.2.10.1. Breast Cancer Drugs Market, Others, 2018 - 2030 (USD Million)
  • 4.3. Hormonal Therapy
    • 4.3.1. Breast Cancer Drugs Market, Hormonal Therapy, 2018 - 2030 (USD Million)
    • 4.3.2. Selective Estrogen Receptor Modulators (Serms)
      • 4.3.2.1. Breast Cancer Drugs Market, Selective Estrogen Receptor Modulators (Serms), 2018 - 2030 (USD Million)
    • 4.3.3. Aromatase Inhibitors
      • 4.3.3.1. Breast Cancer Drugs Market, Aromatase Inhibitors, 2018 - 2030 (USD Million)
    • 4.3.4. Estrogen Receptor Down Regulators (Erds)
      • 4.3.4.1. Breast Cancer Drugs Market, Estrogen Receptor Down Regulators (Erds), 2018 - 2030 (USD Million)
  • 4.4. Chemotherapy
    • 4.4.1. Breast Cancer Drugs Market, Chemotherapy, 2018 - 2030 (USD Million)
  • 4.5. Immunotherapy
    • 4.5.1. Breast Cancer Drugs Market, Immunotherapy, 2018 - 2030 (USD Million)

Chapter 5. Cancer Type Business Analysis

  • 5.1. Breast Cancer Drugs Market: Cancer Type Movement Analysis
  • 5.2. Hormone Receptor
    • 5.2.1. Breast Cancer Drugs Market, Hormone Receptor, 2018 - 2030 (USD Million)
  • 5.3. Her2+
    • 5.3.1. Breast Cancer Drugs Market, Her2+, 2018 - 2030 (USD Million)

Chapter 6. Distribution Channel Business Analysis

  • 6.1. Breast Cancer Drugs Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacies
    • 6.2.1. Breast Cancer Drugs Market, Hospital Pharmacies, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacies
    • 6.3.1. Breast Cancer Drugs Market, Retail Pharmacies, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Breast Cancer Drugs Market, Others, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Breast Cancer Drugs Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. Swot Analysis
    • 7.2.2. North America Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
    • 7.2.3. North America Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
    • 7.2.4. North America Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
    • 7.2.5. U.S.
      • 7.2.5.1. Key Country Dynamics
      • 7.2.5.2. Target Disease Prevalence
      • 7.2.5.3. Competitive Scenario
      • 7.2.5.4. Regulatory Framework
      • 7.2.5.5. Reimbursement Scenario
      • 7.2.5.6. U.S. Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.2.6. Canada
      • 7.2.6.1. Key Country Dynamics
      • 7.2.6.2. Target Disease Prevalence
      • 7.2.6.3. Competitive Scenario
      • 7.2.6.4. Regulatory Framework
      • 7.2.6.5. Reimbursement Scenario
      • 7.2.6.6. Canada Breast Cancer Drugs Market 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Swot Analysis
    • 7.3.2. Europe Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
    • 7.3.3. Europe Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
    • 7.3.4. Europe Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
    • 7.3.5. Germany
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Target Disease Prevalence
      • 7.3.5.3. Competitive Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Reimbursement Scenario
      • 7.3.5.6. Germany Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.6. Uk
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Target Disease Prevalence
      • 7.3.6.3. Competitive Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Reimbursement Scenario
      • 7.3.6.6. Uk Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.7. France
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Target Disease Prevalence
      • 7.3.7.3. Competitive Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Reimbursement Scenario
      • 7.3.7.6. France Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.8. Italy
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Target Disease Prevalence
      • 7.3.8.3. Competitive Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Reimbursement Scenario
      • 7.3.8.6. Italy Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.9. Spain
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Target Disease Prevalence
      • 7.3.9.3. Competitive Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Reimbursement Scenario
      • 7.3.9.6. Spain Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.10. Denmark
      • 7.3.10.1. Key Country Dynamics
      • 7.3.10.2. Target Disease Prevalence
      • 7.3.10.3. Competitive Scenario
      • 7.3.10.4. Regulatory Framework
      • 7.3.10.5. Reimbursement Scenario
      • 7.3.10.6. Denmark Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.11. Sweden
      • 7.3.11.1. Key Country Dynamics
      • 7.3.11.2. Target Disease Prevalence
      • 7.3.11.3. Competitive Scenario
      • 7.3.11.4. Regulatory Framework
      • 7.3.11.5. Reimbursement Scenario
      • 7.3.11.6. Sweden Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.12. Norway
      • 7.3.12.1. Key Country Dynamics
      • 7.3.12.2. Target Disease Prevalence
      • 7.3.12.3. Competitive Scenario
      • 7.3.12.4. Regulatory Framework
      • 7.3.12.5. Reimbursement Scenario
      • 7.3.12.6. Norway Breast Cancer Drugs Market 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Swot Analysis
    • 7.4.2. Asia Pacific Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
    • 7.4.3. Asia Pacific Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
    • 7.4.4. Asia Pacific Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
    • 7.4.5. Japan
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Reimbursement Scenario
      • 7.4.5.6. Japan Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.4.6. China
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Reimbursement Scenario
      • 7.4.6.6. China Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.4.7. India
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. Reimbursement Scenario
      • 7.4.7.6. India Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.4.8. South Korea
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Target Disease Prevalence
      • 7.4.8.3. Competitive Scenario
      • 7.4.8.4. Regulatory Framework
      • 7.4.8.5. Reimbursement Scenario
      • 7.4.8.6. South Korea Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.4.9. Australia
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Target Disease Prevalence
      • 7.4.9.3. Competitive Scenario
      • 7.4.9.4. Regulatory Framework
      • 7.4.9.5. Reimbursement Scenario
      • 7.4.9.6. Australia Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.4.10. Thailand
      • 7.4.10.1. Key Country Dynamics
      • 7.4.10.2. Target Disease Prevalence
      • 7.4.10.3. Competitive Scenario
      • 7.4.10.4. Regulatory Framework
      • 7.4.10.5. Reimbursement Scenario
      • 7.4.10.6. Thailand Breast Cancer Drugs Market 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Swot Analysis
    • 7.5.2. Latin America Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
    • 7.5.3. Latin America Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
    • 7.5.4. Latin America Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
    • 7.5.5. Brazil
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Competitive Scenario
      • 7.5.5.4. Regulatory Framework
      • 7.5.5.5. Reimbursement Scenario
      • 7.5.5.6. Brazil Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.5.6. Mexico
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Competitive Scenario
      • 7.5.6.4. Regulatory Framework
      • 7.5.6.5. Reimbursement Scenario
      • 7.5.6.6. Mexico Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.5.7. Argentina
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Competitive Scenario
      • 7.5.7.4. Regulatory Framework
      • 7.5.7.5. Reimbursement Scenario
      • 7.5.7.6. Argentina Breast Cancer Drugs Market 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. Swot Analysis
    • 7.6.2. MEA Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
    • 7.6.3. MEA Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
    • 7.6.4. MEA Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
    • 7.6.5. South Africa
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Reimbursement Scenario
      • 7.6.5.6. South Africa Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.6.6. Saudi Arabia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Competitive Scenario
      • 7.6.6.4. Regulatory Framework
      • 7.6.6.5. Reimbursement Scenario
      • 7.6.6.6. Saudi Arabia Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.6.7. UAE
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Competitive Scenario
      • 7.6.7.4. Regulatory Framework
      • 7.6.7.5. Reimbursement Scenario
      • 7.6.7.6. UAE Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.6.8. Kuwait
      • 7.6.8.1. Key Country Dynamics
      • 7.6.8.2. Target Disease Prevalence
      • 7.6.8.3. Competitive Scenario
      • 7.6.8.4. Regulatory Framework
      • 7.6.8.5. Reimbursement Scenario
      • 7.6.8.6. Kuwait Breast Cancer Drugs Market 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1 Company Categorization
  • 8.2 Strategy Mapping
    • 8.2.1 New Product Launch
    • 8.2.2 Partnerships
    • 8.2.3 Acquisition
    • 8.2.4 Collaboration
    • 8.2.5 Funding
  • 8.3 Company Market Share Analysis, 2022
  • 8.4 Company Profiles
    • 8.4.1 Novartis Ag
      • 8.4.1.1 Company Overview
      • 8.4.1.2 Financial Performance
      • 8.4.1.3 Product Benchmarking
      • 8.4.1.4 Strategic Initiatives
    • 8.4.2 Pfizer, Inc
      • 8.4.2.1 Company Overview
      • 8.4.2.2 Financial Performance
      • 8.4.2.3 Product Benchmarking
      • 8.4.2.4 Strategic Initiatives
    • 8.4.3 Merck Kgaa
      • 8.4.3.1 Company Overview
      • 8.4.3.2 Financial Performance
      • 8.4.3.3 Product Benchmarking
      • 8.4.3.4 Strategic Initiatives
    • 8.4.4 Janssen Pharmaceuticals, Inc.
      • 8.4.4.1 Company Overview
      • 8.4.4.2 Financial Performance
      • 8.4.4.3 Product Benchmarking
      • 8.4.4.4 Strategic Initiatives
    • 8.4.5 Celgene Corporation, Inc.
      • 8.4.5.1 Company Overview
      • 8.4.5.2 Financial Performance
      • 8.4.5.3 Product Benchmarking
      • 8.4.5.4 Strategic Initiatives
    • 8.4.6 Genzyme Corporation
      • 8.4.6.1 Company Overview
      • 8.4.6.2 Financial Performance
      • 8.4.6.3 Product Benchmarking
      • 8.4.6.4 Strategic Initiatives
    • 8.4.7 F. Hoffmann-La Roche Ltd
      • 8.4.7.1 Company Overview
      • 8.4.7.2 Financial Performance
      • 8.4.7.3 Product Benchmarking
      • 8.4.7.4 Strategic Initiatives
    • 8.4.8 Astrazeneca
      • 8.4.8.1 Company Overview
      • 8.4.8.2 Financial Performance
      • 8.4.8.3 Product Benchmarking
      • 8.4.8.4 Strategic Initiatives
    • 8.4.9 Abbvie Inc.
      • 8.4.9.1 Company Overview
      • 8.4.9.2 Financial Performance
      • 8.4.9.3 Product Benchmarking
      • 8.4.9.4 Strategic Initiatives
    • 8.4.10 Bristol-Myers Squibb Company
      • 8.4.10.1 Company Overview
      • 8.4.10.2 Financial Performance
      • 8.4.10.3 Product Benchmarking
      • 8.4.10.4 Strategic Initiatives
    • 8.4.11 Macrogenics, Inc.
      • 8.4.11.1 Company Overview
      • 8.4.11.2 Financial Performance
      • 8.4.11.3 Product Benchmarking
      • 8.4.11.4 Strategic Initiatives
    • 8.4.12 Celldex Therapeutics
      • 8.4.12.1 Company Overview
      • 8.4.12.2 Financial Performance
      • 8.4.12.3 Product Benchmarking
      • 8.4.12.4 Strategic Initiatives
    • 8.4.13 Onyx Pharmaceuticals Inc.
      • 8.4.13.1 Company Overview
      • 8.4.13.2 Financial Performance
      • 8.4.13.3 Product Benchmarking
      • 8.4.13.4 Strategic Initiatives

Chapter 9 Conclusion

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Breast Cancer Drugs Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 5 Global Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 6 Global Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Breast Cancer Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 9 North America Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 10 North America Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 12 U.S. Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Canada Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 15 Canada Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Canada Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 18 Canada Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 19 Europe Breast Cancer Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 20 Europe Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 21 Europe Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 22 Europe Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Germany Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 24 Germany Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 25 Germany Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 UK Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 27 UK Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 28 UK Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 France Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 30 France Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 31 France Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Italy Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 33 Italy Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 34 Italy Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Spain Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 36 Spain Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 37 Spain Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Denmark Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 39 Denmark Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 40 Denmark Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Sweden Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 42 Sweden Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 43 Sweden Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Norway Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 45 Norway Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 46 Norway Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Breast Cancer Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 China Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 52 China Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 53 China Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 Japan Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 55 Japan Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 56 Japan Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 India Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 58 India Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 59 India Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 South Korea Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 61 South Korea Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 62 South Korea Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Australia Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 64 Australia Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 65 Australia Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Thailand Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 67 Thailand Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 68 Thailand Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Latin America Breast Cancer Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 71 Latin America Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 72 Latin America Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Brazil Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 74 Brazil Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 75 Brazil Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Mexico Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 77 Mexico Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 78 Mexico Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Argentina Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 80 Argentina Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 81 Argentina Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Breast Cancer Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 85 Middle East & Africa Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 South Africa Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 87 South Africa Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 88 South Africa Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 91 Saudi Arabia Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 UAE Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 93 UAE Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 94 UAE Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 97 Kuwait Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 98 Financial performance
  • Table 99 Key companies undergoing expansions
  • Table 100 Key companies undergoing acquisitions
  • Table 101 Key companies undergoing collaborations
  • Table 102 Key companies launching new products/services
  • Table 103 Key companies undergoing partnerships
  • Table 104 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Breast Cancer Drugs Market Segmentation
  • Fig. 7 Market Snapshot, 2022
  • Fig. 8 Market Trends & Outlook
  • Fig. 9 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Market Penetration Vs Growth Prospect Mapping, 2022
  • Fig. 15 Global Breast Cancer Drugs: By Therapy, Movement Analysis
  • Fig. 16 Global Breast Cancer Drugs Market, for Targeted Therapy, 2018 - 2030 (USD Million)
  • Fig. 17 Global Breast Cancer Drugs Market, for Abemaciclib, 2018 - 2030 (USD Million)
  • Fig. 18 Global Breast Cancer Drugs Market, for Ado-Trastuzumab Emtansine, 2018 - 2030 (USD Million)
  • Fig. 19 Global Breast Cancer Drugs Market, for Everolimus, 2018 - 2030 (USD Million)
  • Fig. 20 Global Breast Cancer Drugs Market, for Trastuzumab, 2018 - 2030 (USD Million)
  • Fig. 21 Global Breast Cancer Drugs Market, for Ribociclib2 018 - 2030 (USD Million)
  • Fig. 22 Global Breast Cancer Drugs Market, for Palbociclib, 2018 - 2030 (USD Million)
  • Fig. 23 Global Breast Cancer Drugs Market, for Pertuzumab, 2018 - 2030 (USD Million)
  • Fig. 24 Global Breast Cancer Drugs Market, for Olaparib, 2018 - 2030 (USD Million)
  • Fig. 25 Global Breast Cancer Drugs Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 26 Global Breast Cancer Drugs Market, for Hormonal Therapy, 2018 - 2030 (USD Million)
  • Fig. 27 Global Breast Cancer Drugs Market, for Selective Estrogen Receptor Modulators (SERMs), 2018 - 2030 (USD Million)
  • Fig. 28 Global Breast Cancer Drugs Market, for Aromatase Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 29 Global Breast Cancer Drugs Market, for Estrogen Receptor Down regulators (ERDs), 2018 - 2030 (USD Million)
  • Fig. 30 Global Breast Cancer Drugs Market, for Chemotherapy, 2018 - 2030 (USD Million)
  • Fig. 31 Global Breast Cancer Drugs Market, for Immunotherapy, 2018 - 2030 (USD Million)
  • Fig. 32 Global Breast Cancer Drugs: Cancer Type, Movement Analysis
  • Fig. 33 Global Breast Cancer Drugs Market, for Hormone Receptor, 2018 - 2030 (USD Million)
  • Fig. 34 Global Breast Cancer Drugs Market, for HER2+, 2018 - 2030 (USD Million)
  • Fig. 35 Global Breast Cancer Drugs: Distribution Channel, Movement Analysis
  • Fig. 36 Global Breast Cancer Drugs Market, for Hospital Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 37 Global Breast Cancer Drugs Market, for Retail Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 38 Global Breast Cancer Drugs Market, for Others2018 - 2030 (USD Million)
  • Fig. 39 Regional Marketplace: Key Takeaways Breast Cancer Drugs Market,
  • Fig. 40 Regional Outlook, 2022 & 2030 Breast Cancer Drugs Market,
  • Fig. 41 Global Breast Cancer Drugs Market, Region Movement Analysis
  • Fig. 42 North America Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 44 Canada Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 45 Europe Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 46 Germany Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 47 UK Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 48 France Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 49 Italy Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 50 Spain Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 52 Sweden Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 53 Norway Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 55 Japan Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 56 China Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 57 India Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 58 Australia Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 59 South Korea Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 60 Thailand Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 61 Latin America Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 62 Brazil Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 63 Mexico Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 64 Argentina Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 65 Middle East and Africa Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 66 South Africa Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 67 Saudi Arabia Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 68 UAE Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 69 Kuwait Breast Cancer Drugs Market, 2018 - 2030 (USD Million)